Intermediate for Venetoclax. Venetoclax (trade name Venclexta) is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality. Venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. Venetoclax has been approved by US FDA om April 11, 2016.
Product Name: Ethyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate
CAS Number: 1630101-74-4
Molecular Weight:  361.1943
Molecular Formula:  C16H13BrN2O3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.